Rosuvastatin‐Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study

Patients with rheumatoid arthritis (RA) and carotid artery plaques have an increased risk of acute coronary syndromes. Statin treatment with the goal of achieving a low‐density lipoprotein (LDL) cholesterol level of ≤1.8 mmoles/liter (≤70 mg/dl) is recommended for individuals in the general population who have carotid plaques. The aim of the ROsuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and other inflammatory joint diseases (RORA‐AS) study was to evaluate the effect of 18 months of intensive lipid‐lowering treatment with rosuvastatin with regard to change in carotid plaque height.

[1]  Inge Christoffer Olsen,et al.  Disease activity and left ventricular structure in patients with rheumatoid arthritis. , 2015, Rheumatology.

[2]  L. Punzi,et al.  Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. , 2014, Joint, bone, spine : revue du rhumatisme.

[3]  T. Naqvi,et al.  Carotid intima-media thickness and plaque in cardiovascular risk assessment. , 2014, JACC. Cardiovascular imaging.

[4]  I. Holme,et al.  Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention , 2014, Annals of the rheumatic diseases.

[5]  Vijay Nambi,et al.  Carotid Plaque or CIMT: What is the Future for Carotid US Imaging? , 2014, Current Cardiovascular Risk Reports.

[6]  S. Gabriel,et al.  Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice , 2014, Annals of the rheumatic diseases.

[7]  L. Horn,et al.  Ethnic Disparities in Cardiovascular Risk Factors in Children and Adolescents , 2014, Current Cardiovascular Risk Reports.

[8]  P. Libby,et al.  Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. , 2013, European heart journal.

[9]  W. Dixon,et al.  Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis , 2013, Arthritis and rheumatism.

[10]  Inge Christoffer Olsen,et al.  Carotid Plaque Characteristics and Disease Activity in Rheumatoid Arthritis , 2013, The Journal of Rheumatology.

[11]  I. Holme,et al.  Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic , 2012, Annals of the rheumatic diseases.

[12]  I. Holme,et al.  Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. , 2012, Arthritis and rheumatism.

[13]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[14]  Peter Libby,et al.  Effect of two intensive statin regimens on progression of coronary disease. , 2011, The New England journal of medicine.

[15]  D. O'leary,et al.  Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. , 2011, Arthritis and rheumatism.

[16]  M. Quinn,et al.  Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2011, Rheumatology.

[17]  D. Atar,et al.  Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study , 2011, Annals of the rheumatic diseases.

[18]  M. Hochberg,et al.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[19]  M. González-Gay,et al.  Insulin resistance in rheumatoid arthritis: the impact of the anti‐TNF‐α therapy , 2010, Annals of the New York Academy of Sciences.

[20]  P. Kiely,et al.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.

[21]  G. Kitas,et al.  Atherosclerosis in Rheumatoid Arthritis Versus Diabetes: A Comparative Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[22]  C. Liapis,et al.  Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. , 2009, Journal of vascular surgery.

[23]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[24]  M. Dougados,et al.  Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[25]  T. Therneau,et al.  The widening mortality gap between rheumatoid arthritis patients and the general population. , 2007, Arthritis and rheumatism.

[26]  B. Tomlinson,et al.  Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis , 2007, Clinical Rheumatology.

[27]  P. McBride,et al.  Ultrasound-detected carotid plaque as a predictor of cardiovascular events , 2006, Vascular medicine.

[28]  Richard B Devereux,et al.  Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis , 2006, Annals of Internal Medicine.

[29]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[30]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[31]  Sheng Kang,et al.  Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. , 2004, Atherosclerosis.

[32]  A. Smit,et al.  Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. , 2004, Circulation.

[33]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[34]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[35]  P. Shekelle,et al.  How to read radiographs according to the Sharp/van der Heijde method. , 1999 .

[36]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[37]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[38]  B. J. Gersh.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .

[39]  A. V. van Gammeren,et al.  Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification , 2008, Clinical chemistry and laboratory medicine.

[40]  D. M. van der Heijde,et al.  How to read radiographs according to the Sharp/van der Heijde method. , 1999, The Journal of rheumatology.

[41]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.